Board of Advisors
Julius M. Wilder MD, PHD
Dr. Julius Wilder obtained the first MD, PhD in Medical Sociology in the history of Duke University. Following medical school and graduate school he completed a residency in internal medicine at Duke where he served as an Assistant Chief Resident. At the end of his residency, Dr. Wilder completed a fellowship in gastroenterology and an advanced transplant hepatology fellowship at Duke. He is an Assistant Professor of Medicine and has a tenure-track faculty appointment in the Duke School of Medicine, the Duke Clinical Research Institute, and the Duke Department of Sociology (secondary appointment). He serves on the Duke School of Medicine executive admissions committee, Duke School of Medicine institutional review committee, and is the Diversity Chair for the Duke Division of Gastroenterology.
Dr. Wilder has numerous publications and has won awards for his research in hepatology, GI, and on social determinants of health. He is the Principal Investigator (PI) or Co-PI on multiple clinical trials in gastroenterology, hepatology and transplant hepatology. His clinical duties include working as a gastroenterologist/hepatologist at Duke University and Duke Regional Hospitals in Durham, North Carolina.
Karin Jorga, PhD
Dr. Karin Jorga, PhD, has over 20 years of experience in drug development of small and large molecules across all therapeutic areas. The focus of her international experience has been on transitioning pre-clinical lead molecules to Clinical Proof-of-Concept and advancing novel biomarkers to drive Personalized Healthcare. She has a substantial scientific track record in Clinical Pharmacology and a unique set of expertise that includes the usage of Biomarkers and application of Computer Models to overcome drug development hurdles and drive scientifically sound decision making.
Dr. Jorga’s past experience includes being the Global Head of Biomarker Technology and Science, Global Head of Clinical Pharmacology, and Global Head of Modeling and Simulation at Roche.
She currently runs a consulting firm, KarinJorga Life Science Consulting, that was founded in 2014 in Basel with the ambition to develop scientific innovations into medicines for tomorrow.
Kelly W Padilla, BSPharm PharmD
Dr. Padilla is a clinical pharmacist of over 20 years who has served in many clinical leadership roles within the pharmaceutical industry: global clinical supplies, regulatory affairs regulatory intelligence, medical writing, global medical affairs, medical communications, and hospital pharmacy.
She has been the global medical information lead for several product launches and has been a functional head in several pivotal trials in respiratory, oncology, HIV, CNS, urology, and orthopedics; for both small molecules and biologics. Kelly holds a Doctor of Pharmacy from the University of Florida, and a Bachelor of Science of Pharmacy from the University of North Carolina – Chapel Hill.
Dr. Padilla is also a graduate of the prestigious NC School of Science and Mathematics.
Personal: Outside of work, Kelly plays the flute and dances salsa. She enjoys traveling and cuddling with her 2 daughters and fur-baby Naomi the poodle.
Richard A. Graham, Ph.D., was appointed Senior Vice President, Development in August 2020, where he is responsible for leading the progression of late-stage clinical assets through regulatory filing and approval. Since joining Theravance Biopharma, Dr. Graham has served as Vice President of Clinical Pharmacology, and more recently, as Vice President of Clinical Development.
Prior to joining Theravance Biopharma, Dr. Graham spent five years at GlaxoSmithKline working in the area of Drug Metabolism and Pharmacokinetics, seven years at Genentech/Roche as a clinical pharmacologist and Global Development Team Leader, and one year at Onyx Pharmaceuticals where he headed Translational Medicine. In his nearly 20-year career, he worked across all stages of drug development and all major therapeutic areas.
Dr. Graham received his Bachelor’s and Master’s degree in Biochemistry from Iowa State University and his Doctorate of Philosophy degree in Pharmaceutical Sciences from The University of North Carolina at Chapel Hill.
Baljit (Boo) Samra
Baljit (Boo) Samra, is currently Corporate Senior Vice President and Head of Clinical Operations, Asia Pacific at Parexel. Prior to this position, Boo was the Chief Operating Officer (COO) at Duke Clinical Research Institute (DCRI) for three years. He has over 25 years of experience in clinical trials, primarily with CROs and Academic Medical Centers, and is a seasoned leader with global expertise in operations, digital health and technologies, account leadership, quality management, and general management. Having lived in the UK, USA, and Asia, including China, Japan, India, and now Singapore, his work experience spans the globe.
Dan Ballard has over 20 years of experience within various segments of the pharmaceutical industry. He is passionate about the digitalization of consumable data assets to accelerate the transformation of the pharmaceutical industry. He currently serves on multiple boards associated with the Labcorp Venture Fund in addition to this Scientific Advisory role with Trulab.
Dan joined Labcorp Drug Development in 2018 as the Executive Director of Global Data Strategy and now leads the Global Digital, Data, Platforms, and Architecture teams. Prior to working for Labcorp Drug Development, he was previously the Head of Enterprise Data Governance and Clinical Informatics for IQVIA and prior to that was Vice President and GM, Prescriber Access at Cegedim.
In addition to professional experience, Dan earned a BS in Political Science from the United States Naval Academy. After completing his undergraduate degree, he served in the US Marine Corps for over 11 years. Dan continued his education at the UNC Kenan-Flagler Business School and received an MBA with a concentration in operations.
TruLab’s board of advisors possesses a collective 126 years of experience in the pharmacological and medical fields.
This experience of our board is invaluable to the executive team and influences every decision we make as a company.